20240018157. CYCLIC COMPOUNDS AND METHODS OF USING SAME simplified abstract (Schrödinger, Inc.)

CYCLIC COMPOUNDS AND METHODS OF USING SAME

Organization Name

Schrödinger, Inc.

Inventor(s)

Shulu Feng of New York NY (US)

Morgan Lawrenz of San Diego CA (US)

Goran Krilov of Long Island NY (US)

Andrew Placzek of Portland OR (US)

Zhe Nie of San Diego CA (US)

Lynnie Trzoss of San Diego CA (US)

Michael Trzoss of San Diego CA (US)

Haifeng Tang of Metuchen NJ (US)

H. Rachel Lagiakos of Brooklyn NY (US)

CYCLIC COMPOUNDS AND METHODS OF USING SAME - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240018157 titled 'CYCLIC COMPOUNDS AND METHODS OF USING SAME

Simplified Explanation

The present patent application is about compounds of formula (i) and their pharmaceutically acceptable salts, which act as MALT1 inhibitors. The application also describes a pharmaceutical composition containing a compound of formula (i) and its salts, as well as methods of using these compounds and compositions to treat diseases such as cancer, autoimmune disorders, and inflammatory disorders.

• Compounds of formula (i) and their pharmaceutically acceptable salts are disclosed in the patent application.
• These compounds act as MALT1 inhibitors, which means they can inhibit the activity of MALT1 enzyme.
• The patent application also describes a pharmaceutical composition comprising a compound of formula (i) and its salts, which can be used for the treatment of diseases.
• The disclosed methods involve using the compounds and compositions to treat diseases such as cancer, autoimmune disorders, and inflammatory disorders.

Potential applications of this technology:

• Treatment of cancer: The compounds and compositions described in the patent application can be used for the treatment of various types of cancer.
• Treatment of autoimmune disorders: The technology can be applied to develop therapies for autoimmune disorders, where the immune system mistakenly attacks healthy cells.
• Treatment of inflammatory disorders: The compounds and compositions can be used to alleviate inflammation associated with various disorders.

Problems solved by this technology:

• Lack of effective treatments: The technology provides new compounds and compositions that can potentially offer improved treatment options for diseases such as cancer, autoimmune disorders, and inflammatory disorders.
• Inadequate MALT1 inhibition: By acting as MALT1 inhibitors, the compounds described in the patent application address the need for more effective inhibition of this enzyme, which plays a role in various disease processes.

Benefits of this technology:

• Improved treatment options: The compounds and compositions described in the patent application offer potential new treatment options for diseases that currently have limited therapeutic choices.
• Targeted therapy: By specifically inhibiting MALT1, the technology may provide more targeted and precise therapies, potentially reducing side effects associated with non-specific inhibition of other enzymes or pathways.

Original Abstract Submitted

the present application relates to compounds of formula (i), as defined herein, and pharmaceutically acceptable salts thereof which are malt1 inhibitors. the present application also describes pharmaceutical composition comprising a compound of formula (i), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.